Cargando…

Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review

SIMPLE SUMMARY: Hodgkin lymphoma (cHL) in older adults is typically characterized by a prognosis that is markedly worse than that of young patients, due to both greater difficulty in achieving adequate disease control and higher treatment-related toxicity. Although rarely included in clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zilioli, Vittorio Ruggero, Muzi, Cristina, Pagani, Chiara, Ravano, Emanuele, Meli, Erika, Daffini, Rosa, Ravelli, Erika, Cairoli, Roberto, Re, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000520/ https://www.ncbi.nlm.nih.gov/pubmed/36900306 http://dx.doi.org/10.3390/cancers15051515

Ejemplares similares

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
por: Rusconi, Chiara, et al.
Publicado: (2022)

P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
por: Rusconi, Chiara, et al.
Publicado: (2023)

Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin’s lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience
por: Zilioli, Vittorio R, et al.
Publicado: (2020)

Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experience
por: Zilioli, Vittorio Ruggero, et al.
Publicado: (2021)

The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments
por: Bari, Alessia, et al.
Publicado: (2019)

P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
por: Rusconi, Chiara, et al.
Publicado: (2022)

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
por: De Re, Valli, et al.
Publicado: (2019)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma
por: De Re, Valli, et al.
Publicado: (2022)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

The molecular mechanisms of classic Hodgkin's lymphoma.
por: Felberbaum, Rachael S.
Publicado: (2005)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

Comparison between skeletal muscle and adipose tissue measurements with high-dose CT and low-dose attenuation correction CT of (18)F-FDG PET/CT in elderly Hodgkin lymphoma patients: a two-centre validation
por: Albano, Domenico, et al.
Publicado: (2021)

The outcome of older adults with classic Hodgkin lymphoma in British Columbia
por: Cheng, Phoebe T. M., et al.
Publicado: (2022)

Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose?
por: Takiar, Radhika, et al.
Publicado: (2022)

Bob-1 is expressed in classic Hodgkin lymphoma
por: Abd El All, Howayda S
Publicado: (2007)

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma
por: Relecom, Allan, et al.
Publicado: (2020)

MicroRNA signature in classical Hodgkin lymphoma
por: Paczkowska, Julia, et al.
Publicado: (2021)

Bone marrow involvement by classic Hodgkin lymphoma
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Aberrant synaptophysin expression in classic Hodgkin lymphoma
por: Im, Soyoung, et al.
Publicado: (2022)

Current directions in the treatment of classical Hodgkin lymphoma
por: Keller, Frank G., et al.
Publicado: (2023)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

Treatment of very high-risk classical Hodgkin Lymphoma: cases’ selection from real life and critical review of the literature
por: Rusconi, Chiara, et al.
Publicado: (2020)

Options for first line therapy of Hodgkin lymphoma
por: Longley, Jemma, et al.
Publicado: (2019)

P054: The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma
por: Visentin, Andrea, et al.
Publicado: (2022)

Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry
por: Biasoli, Irene, et al.
Publicado: (2023)

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future
por: Richardson, S. E., et al.
Publicado: (2011)

Hemophagocytic Lymphohistiocytosis in a Patient with Classical Hodgkin Lymphoma
por: Hyun, G., et al.
Publicado: (2016)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Combined linkage and association analysis of classical Hodgkin lymphoma
por: Lawrie, Alastair, et al.
Publicado: (2018)

Mucocutaneous Paraneoplastic Syndrome Secondary to Classical Hodgkin’s Lymphoma
por: Jurkovic, Jenna, et al.
Publicado: (2019)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Cell-Free DNA for the Management of Classical Hodgkin Lymphoma
por: Camus, Vincent, et al.
Publicado: (2021)

Classical Hodgkin Lymphoma Presenting as a Sigmoid Mass
por: Caulkins, Heather, et al.
Publicado: (2021)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Optimization of the first line treatment in classical Hodgkin's lymphoma
por: Brice, Pauline
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a231q66dh3oe66ua5tscdc5u5t